Synairgen* (SNG): First patient dosed in COPD Phase IIa study (CORP) | Transense Technologies* (TRT): Interim results, good momentum into 2H (CORP) | SimiGon* (SIM): USAF contract extension (CORP)
07 Feb 2018
Morning Note
Sign up to access
Get access to our full offering from over 30 providers
Get access to our full offering from over 30 providers
Morning Note
- Published:
07 Feb 2018 -
Author:
David Buxton | Mark Brewer | Cavendish Research -
Pages:
5
Synairgen* (SNG): First patient dosed in COPD Phase IIa study (CORP) | Transense Technologies* (TRT): Interim results, good momentum into 2H (CORP) | SimiGon* (SIM): USAF contract extension (CORP)